Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Next Previous
Trial Profile

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Enasidenib (Primary) ; Everolimus (Primary) ; Irinotecan (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Ribociclib (Primary) ; Temozolomide (Primary) ; Topotecan (Primary) ; Vistusertib (Primary)
  • Indications Brain cancer; Carcinoma; Diffuse intrinsic pontine glioma; Ependymoma; Ewing's sarcoma; Glioblastoma; Glioma; Haematological malignancies; Hepatoblastoma; Leukaemia; Malignant melanoma; Medulloblastoma; Meningioma; Nerve sheath neoplasms; Neuroblastoma; Neuroepithelial neoplasms; Neurofibromatoses; Oligodendroglioma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdoid tumour; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms AcSe-ESMART; ESMART

Most Recent Events

  • 10 Jan 2025 Planned number of patients changed from 460 to 455.
  • 10 Jan 2025 Planned End Date changed from 1 Aug 2027 to 1 Feb 2031.
  • 10 Jan 2025 Planned primary completion date changed from 1 Aug 2027 to 1 Feb 2031.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top